In line with this assumption, the application of leptin was associated with significant enhanced TAA-induced liver disease, while the application of a competitive leptin inhibitor attenuated chemically induced hepatic fibrosis in mice and suppressed profibrogenic potential of HSC (Elinav et al., 2009). The gene discussed is LEP; the disease is Hepatic fibrosis.